Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

Thursday, September 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx Limited has announced the launch of the DETECSEPS program in France, aimed at enhancing the early detection of sepsis. This initiative is part of a government-funded consortium and aligns with the company's mission to innovate in disease diagnosis and monitoring. The project highlights Volition's commitment to addressing critical health challenges.

Market Sentiment Analysis

POSITIVE FACTORS

  • VolitionRx is advancing early detection of sepsis.
  • The DETECSEPS program is government-funded, indicating strong support.
  • The initiative aligns with Volition's mission to improve disease diagnosis.

Full Press Release Details

HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.
DETECSEPS aligns with Volition's core purpose – to revolutionize the diagnosis and monitoring of life-altering diseases such as sepsis.

Frequently Asked Questions

What is the DETECSEPS program?

The DETECSEPS program focuses on the early detection of sepsis.

Who is funding the DETECSEPS initiative?

The DETECSEPS program is funded by the government.

What is VolitionRx's mission?

VolitionRx aims to revolutionize the diagnosis and monitoring of diseases.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx sepsis detection DETECSEPS epigenetics France
Last updated: Sep 17, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk